ASCO24 Updates: Survival Outcomes: Neoadjuvant vs. Adjuvant Therapy in NSCLC

Adjuvant Versus Neoadjuvant Therapy in NSCLCПодробнее

ASCO24 Highlights: Advances in NSCLCПодробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

OncTalk 2021 - Neoadjuvant Therapy vs. Adjuvant Therapy: What is the Future Role?Подробнее

Adjuvant Versus Neoadjuvant Chemotherapy for NSCLCПодробнее

Practical Considerations for Adjuvant vs. Neoadjuvant Immunotherapy in NSCLCПодробнее

For NSCLC Neoadjuvant Adjuvant or BothПодробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancerПодробнее

Immunotherapy at ASCO 2023: updates in neoadjuvant and adjuvant therapyПодробнее

Key Takeaways From ESMO: Adjuvant and Neoadjuvant Therapy for NSCLCПодробнее

Immunotherapy at ASCO24: NADINA and Other Key StudiesПодробнее

Highlights in lung cancer from ASCO 2024Подробнее

Adjuvant taxane + anthracycline therapy in HR+/HER2- BC with high RS valuesПодробнее

Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapyПодробнее

Clinical trials of neoadjuvant targeted therapy in resectable NSCLCПодробнее

Trial updates in neoadjuvant adjuvant therapies for early-stage NSCLCПодробнее

GU Oncology Highlights From ASCO24Подробнее